Serra-Peptidase For Life is a proprietary high potency enzyme
preparation delivering 400 IU of enterically coated granules. Other inferior brands do not have the enteric coating needed for proper absorbtion and utilization by our bodies.
Serrapeptidase has been
used to treat:
pain and strain
inflammation
rheumatoid arthritis
osteo-arthritis
lupus
fibrocystic breast disease
ovarian cysts
ear nose & throat infections
bronchitis and asthma
emphysema
fibromyalgia
Crohn’s disease
colitis and cystitis
enlarged prostate
post-operative swelling
varicose veins
thrombophlebitis
migraines
sprains and trauma
arterial plaque
Clinical studies show that serrapeptase induces fibrinolytic, anti-inflammatory and anti-edemic (prevents swelling and fluid retention) activity in a number of tissues, and that its anti-inflammatory effects are superior to other proteolytic enzymes.
Besides reducing inflammation, one of serrapeptase's most profound benefits is reduction of pain, due to its ability to block the release of pain-inducing amines from inflamed tissues. Physicians throughout Europe and Asia have recognized the anti-inflammatory and pain-blocking benefits of this naturally occurring substance and are using it in treatment as an alternative to salicylates, ibuprofen, and other NSAIDs.
In Germany and other European countries, serrapeptase is a common treatment for inflammatory and traumatic swellings, and much of the research that exists on this substance is of European origin. One double-blind study was conducted by German researchers to determine the effect of serrapeptase on post-operative swelling and pain. This study involved sixty-six patients who were treated surgically for fresh rupture of the lateral collateral ligament of the knee. On the third post-operative day, the group receiving serrapeptase exhibited a 50 percent reduction of swelling, compared to the controls. The patients receiving serrapeptase also became more rapidly pain-free than the controls, and by the tenth day, the pain had disappeared completely.
What the Research Shows
Ear, Nose, and Throat Conditions
A study of 193 patients with acute or chronic ear, nose and throat pathologies (including laryngitis). After 3-4 days, patients taking serrapeptidase experienced a significant reduction in pain, secretion and other symptoms. Improvement was excellent or good for 97.3% of the serrapeptidase patients, compared with only 21.9% of the placebo patients.(1)
Respiratory Conditions
In respiratory diseases characterized by increased production of dense mucus, serrapeptidase alters mucus elasticity and results in a considerable reduction in viscosity, confirming its efficacy as a mucolytic agent.(2,3,4) A Japanese study of patients with chronic airway diseases found that treatment with serrapeptidase caused symptoms to significantly decrease, and exerted a beneficial effect on mucus clearance.(5) A double-blind study of 174 patients found the degree of swelling in serrapeptidase-treated patients was consistently and significantly less than in the placebo group, without side effects.(6)
Fibrocystic Breast Disease
In a double-blind study of 70 patients with fibrocystic breast disease, 85.7% of the patients receiving serrapeptidase reported moderate to marked improvement in breast pain, swelling and firmness. No adverse reactions were reported and researchers concluded that "Serrapeptidase is a safe and effective method for the treatment of breast engorgement".(7,8)
Post-operative Swelling
In a German study, patients who had ankle ligament surgery and were given serrapeptidase had a 50% reduction in swelling after 3 days, while patients in two control groups had no reduction in swelling. The serrapeptidase patients also recovered more rapidly than the controls, becoming pain-free by the 10th day.(9)
Other Conditions
In a 6-week study of 20 carpal tunnel syndrome patients, 65% showed significant clinical improvement supported by significant improvement in electrophysiological parameters.(10) In an Italian study of 20 patients with varicose veins, good to excellent improvement was reported in over 60% of the subjects taking serrapeptidase. Pain was reduced in 63% of cases, fluid buildup in 56%, and abnormal skin redness in 58%.(11)
References:
1. Mazzone A, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88.
2. Tomoda K, and Miyatam K. Some information on the composition of trachael secretions before and after the administration of Danzen. Exper Ther. 1972; 477:9-16.
3. Marriott C. Modification in the rheological properties of mucus by drugs. Adv Exp Med Biol. 1982; 144:75-84.
4. Carratu L, et al. Physico-chemical and rheological research on mucolytic activity of serratio-peptidase in chronic broncho-pneumopathies. Therapeutic Res. Dec 1980; 937-951.
5. Nakamura S, et al. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology Vol 8 #3, Sept 2003, p.316-320 doi:10.1046/j.1440-1843.2003.00482.
6. Tachibana M, et al. A muti-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica; 1984; 3(8); 526-30.
7. Kee WH, Tan SL, Lee V, Salmon YM. The treatment of breast engorgement with serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med J. 1989;30(1):48-54.
8. Aso T et al. Breast engorgement and its treatment: Clinical effects of Danzen an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynecology (Japanese). 1981; 33:371-9.
9. Esch, PM, et al. Reduction of post-operative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase – a prospective study. Fortschr Med. 1989 Feb 10; 107(4):67-8, 71-2.
10. Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India; 1999; 47 (12); 1170-1172.
11. Minerva Cardioangiol, Vol. No. 10, October 1996: 515-24.
Free online holistic health consultationsClick here.
